L'hospitalet De Llobregat

• A trial to learn how well durvalumab and chemotherapy with or without tremelimumab work in adults with advanced cancer of the bladder or uri … Ended recruitment
  2024-510976-19-00 5 2018-11-30 Patients with Unresectable Locally Advanced or Metastatic Urothelial C
• Study to evaluate the efficacy of 3 different treatments, followed by maintenance treatment, in older adult patients, between 65 and 80 year … Ended recruitment
  2024-516905-22-00 5 2018-10-22 Multiple myeloma
• Clinical trial to compare the efficacy of two treatment sequencing schemes with chemotherapy (the regime called FOLFOX and FOLFIRI) in combi … Ended recruitment
  2024-510967-41-00 5 2018-09-21 Metastatic colorectal cancer
• Randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck Ended recruitment
  2024-513206-65-00 5 2018-08-10 resected squamous cell carcinoma of head and neck
• A Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-9545 Alone or in Combination with Palbociclib and/or LHRH Agonist in Pa … Ended recruitment
  2023-506700-12-00 3 2018-06-18 Locally Advanced or Metastatic Estrogen Receptor−Positive Breast Cance
• A Phase 3 Study of Zanubrutinib (BGB-3111) Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocyt … Ended recruitment
  2023-509976-40-00 5 2018-05-28 Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
• A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma Ended recruitment
  2023-504802-12-00 7 2018-05-16 Lymphoma of B-cell origin
• Talquetamab (GPRC5D and CD3 antibody) in Relapsed or Refractory Multiple Myeloma Ended recruitment
  2023-504581-29-00 7 2018-04-26 Multiple myeloma
• A Study of Glofitamab (RO7082859) and Atezolizumab or Polatuzumab Vedotin (Plus A Single Pretreatment Dose of Obinutuzumab) in Adult Patient … Ended recruitment
  2023-505222-34-00 7 2018-04-23 Relapsed/refractory (r/r) B-cell Non-Hodgkin’s Lymphoma (NHL)
• Chemo +/- Pembrolizumab (MK-3475) as Perioperative Therapy for Stage II, IIIA-Resectable IIIB (N2) NSCLC Ended recruitment
  2023-504820-24-00 5 2018-03-21 Neoadjuvant/Adjuvant treatment for participants with Resectable Stage
• Transplant BRaVE NHL: Phase I-II study combining Brentuximab Vedotin with second line salvage chemotherapy (R-DHAP) in CD30 positive diffuse … Ended recruitment
  2023-510556-22-00 4 2018-03-05 non-Hodgkin lymphoma (NHL)
• Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE) Ended recruitment
  2023-510444-21-00 5 2017-11-24 Neuroendocrine tumours of gastroenteric or pancreatic origin
• A Placebo controlled Maintenance and Long-term Extension Study of the Efficacy and Safety of Risankizumab in Participants with Crohn's Disea … Ended recruitment
  2023-506399-28-00 5 2017-11-08 Crohn's Disease
• Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib Ended recruitment
  2023-507329-40-00 6 2017-09-28 1. Follicular Lymphoma 2. Chronic Lymphocytic Leukemia 3. Waldenstrom
• A Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small C … Ended recruitment
  2023-507500-31-00 10 2017-08-22 Advanced or metastatic Non-small cell lung cancer (NSCLC)
• A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination wi … Ended recruitment
  2023-509354-58-00 5 2017-07-14 Mantle Cell Lymphoma
• Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer after FDG-PET response-adapted strategy. The PHERGain study Ended recruitment
  2023-509923-42-00 4 2017-07-06 HER2- positive breast cancer
• A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors Ended recruitment
  2023-506390-35-00 1 2017-04-19 Patients with Advanced Solid Tumors
• Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Expos … Ended recruitment
  2022-501763-40-00 5 2016-12-13 Pre-Exposure Prophylaxis of HIV-1 Infection
• A study to decide what is the highest dose of CC-220 to take alone and with other standard of care treatments to assess the side effects, ef … Ended recruitment
  2024-510799-19-00 9 2016-08-09 Multiple Myeloma
• An Efficacy and Safety Study of JNJ56021927 (ARN509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS Ended recruitment
  2023-505246-26-00 5 2016-01-27 High- or very-high risk, localized or locally advanced prostate cancer
• EORTC-1407-GUCG: A randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) wit … Ended recruitment
  2024-513509-30-00 5 2016-01-11 Progressive or recurrent germ cell tumor (measurable or non-measurable
• PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy vers … Ended recruitment
  2024-514841-12-00 5 2015-10-27 To determine whether the addition of palbociclib to adjuvant endocrine
• A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High R … Ended recruitment
  2023-509347-27-00 5 2015-09-30 High Risk Chronic Lymphocytic Leukaemia

Showing 769–792 of 1,017 trials